UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis

British journal of clinical pharmacology, 2022-05, Vol.88 (5), p.2359-2371

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women

British journal of clinical pharmacology, 2018-08, Vol.84 (8), p.1839-1855

2018

Link zum Volltext

Verfügbarkeit prüfen

Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

Scientific reports, 2021-03, Vol.11 (1), p.6404-10, Article 6404

2021

Link zum Volltext

Verfügbarkeit prüfen

Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

British journal of clinical pharmacology, 2019-07, Vol.85 (7), p.1516-1527

2019

Link zum Volltext

Verfügbarkeit prüfen

c-Jun NH2 -terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study

Fertility and sterility, 2016-03, Vol.105 (3), p.815-824.e5

2016

Link zum Volltext

Verfügbarkeit prüfen

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments

Clinical pharmacology in drug development, 2018-11, Vol.7 (8), p.889-900

2018

Link zum Volltext

Verfügbarkeit prüfen

Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models

Reproductive sciences (Thousand Oaks, Calif.), 2016-01, Vol.23 (1), p.11-23

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Fertility and sterility, 2020-07, Vol.114 (1), p.44-55

2020

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of c‐Jun N‐terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats

British journal of pharmacology, 2004-07, Vol.142 (6), p.953-960

2004

Link zum Volltext

Verfügbarkeit prüfen

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern

Reproductive sciences (Thousand Oaks, Calif.), 2020-04, Vol.27 (4), p.988-995

2020

Link zum Volltext

Verfügbarkeit prüfen

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109

The journal of clinical endocrinology and metabolism, 2018-02, Vol.103 (2), p.497-504

2018

Link zum Volltext

Verfügbarkeit prüfen

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

The Lancet (British edition), 2022-09, Vol.400 (10356), p.896-907

2022

Link zum Volltext

Verfügbarkeit prüfen

Design and Synthesis of the First Generation of Novel Potent, Selective, and in Vivo Active (Benzothiazol-2-yl)acetonitrile Inhibitors of the c-Jun N-Terminal Kinase

Journal of medicinal chemistry, 2005-07, Vol.48 (14), p.4596-4607

2005

Link zum Volltext

Verfügbarkeit prüfen

Control of death receptor and mitochondrial‐dependent apoptosis by c‐Jun N‐terminal kinase in hippocampal CA1 neurones following global transient ischaemia

Journal of neurochemistry, 2005-03, Vol.92 (5), p.1054-1060

2005

Link zum Volltext

Verfügbarkeit prüfen

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F 2α -induced Contractions and Inflammatory Responses in Human Myometrium

Scientific reports, 2019-12, Vol.9 (1), p.5792

2019

Link zum Volltext

Verfügbarkeit prüfen

The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers

Reproductive biomedicine online, 2021-08, Vol.43 (2), p.184-192

2021

Link zum Volltext

Verfügbarkeit prüfen

AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties

The Journal of pharmacology and experimental therapeutics, 2004-07, Vol.310 (1), p.25

2004

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age

Reproductive sciences (Thousand Oaks, Calif.), 2014-10, Vol.21 (10), p.1256-1265

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers

Multiple sclerosis, 2011-01, Vol.17 (1), p.43-56

2011

Link zum Volltext

Verfügbarkeit prüfen

A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys

Regulatory toxicology and pharmacology, 2013-06, Vol.66 (1), p.6-12

2013

Link zum Volltext

Verfügbarkeit prüfen

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

Scientific reports, 2019-04, Vol.9 (1), Article 5792

2019

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids

Reproductive sciences (Thousand Oaks, Calif.), 2015-04, Vol.22 (4), p.476-483

2015

Link zum Volltext

Verfügbarkeit prüfen

Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium

Molecular pharmacology, 2017-04, Vol.91 (4), p.403-415

2017

Link zum Volltext

Verfügbarkeit prüfen

Treatment of female rhesus macaques with a somatostatin receptor antagonist that increases oocyte fertilization rates without affecting post-fertilization development outcomes

Journal of assisted reproduction and genetics, 2019-02, Vol.36 (2), p.229-239

2019

Link zum Volltext

Verfügbarkeit prüfen

Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole

International journal of clinical pharmacology and therapeutics, 2013-01, Vol.51 (1), p.26

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(53)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(28)
Female
(21)
Humans
(20)
Animals
(16)
Pharmacology & Pharmacy
(14)
Adult
(10)
Biological And Medical Sciences
(9)
Chemistry
(8)
Dose-Response Relationship, Drug
(8)
Middle Aged
(8)
Obstetrics & Gynecology
(8)
Rats
(8)
Reproductive Biology
(8)
Young Adult
(8)
Jnk Mitogen-Activated Protein Kinases - Antagonists & Inhibitors
(7)
Medical Sciences
(7)
Administration, Oral
(6)
Mice
(6)
Pharmacology. Drug Treatments
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women

Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

c-Jun NH2 -terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments

Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Inhibition of c‐Jun N‐terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

Design and Synthesis of the First Generation of Novel Potent, Selective, and in Vivo Active (Benzothiazol-2-yl)acetonitrile Inhibitors of the c-Jun N-Terminal Kinase

Control of death receptor and mitochondrial‐dependent apoptosis by c‐Jun N‐terminal kinase in hippocampal CA1 neurones following global transient ischaemia

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F 2α -induced Contractions and Inflammatory Responses in Human Myometrium

The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers

AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties

Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age

Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers

A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids

Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium

Treatment of female rhesus macaques with a somatostatin receptor antagonist that increases oocyte fertilization rates without affecting post-fertilization development outcomes

Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole

Suchergebnisse filtern